Could these twins' rare genetic disorder provide the key to preventing cancer? It's an intriguing question that delves into the potential of Laron syndrome, a condition that affects only 840 people worldwide. This article explores the fascinating story of how a rare genetic disorder might hold the key to cancer prevention, and the personal journey of the twins who live with this condition.
The story begins in the remote town of Piñas, Ecuador, where the sisters María Luísa Romero and María del Cisne reside. They are among the few people globally with Laron syndrome, a condition that prevents them from growing taller than 3.9 feet. While living with Laron syndrome can be challenging, the sisters find strength in their bond, sharing their experiences and supporting each other.
The condition is named after paediatrician Zvi Laron, who identified it 60 years ago while treating patients in Israel. It is caused by a mutation in the growth hormone receptor in the liver, which prevents the body from using the growth hormone. This results in short stature and a unique set of challenges for those affected.
What makes Laron syndrome particularly intriguing is the lower incidence of diseases like cancer and diabetes among those with the condition. Researchers, including Dr. Jaime Guevara and Dr. Valter Longo, have been studying this phenomenon. They found that Laron patients have lower levels of Insulin-like Growth Factor 1 (IGF-1), which may prevent cancer cells from dying. This discovery has led to the idea that replicating this process through drugs or diets could potentially prevent cancer in others.
However, the research is still in its early stages, and more work is needed before any treatments can become a reality. Prof. Laron, who has been studying the syndrome for decades, acknowledges that IGF-1 levels are only part of the explanation. Ongoing research on mice and pigs aims to uncover the full reason for the lower cancer incidence.
The twins' personal journey with Laron syndrome is also a powerful aspect of this story. They mistakenly believed they were immune to cancer, but one of them was diagnosed with colon cancer, serving as a wake-up call. This experience highlights the importance of self-care and the challenges of living with a rare genetic disorder.
Access to treatment, such as the drug Increlex, is another critical aspect. While it can help increase height during growth spurts, it is expensive and has limitations. The twins, who missed the window for taking the drug in their youth, reflect on how their lives might have been different with early treatment.
In conclusion, the story of Laron syndrome and its potential connection to cancer prevention is a captivating one. It raises questions about the power of genetic disorders to offer insights into disease prevention and the importance of continued research. The personal stories of the twins add a layer of humanity to this scientific exploration, reminding us of the impact of these rare conditions on individuals and their families.
